Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655441 · ClinicalTrials.gov registry record · Phase 4
The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function
A Phase 4 study, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT06655441 is a Phase 4 study that is actively recruiting participants, run by Southern California College of Optometry at Marshall B. Ketchum University. The registered enrollment target is 30 participants.
The verdict
NCT06655441, a Phase 4 study, is actively recruiting participants, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the effects of trehalose, an ingredient found in commercially available artificial tears, on the corneal barrier function. The investigators will assess corneal dryness and measure the relative corneal epithelial "barrier" function (the degree to which the cornea can prevent penetration of sodium fluorescein dye into the eye) after using eye drops that contain 3% trehalose for one month.
Interventions
- DRUG 3% trehalose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06655441
The ClinicalTrials.gov registry entry for NCT06655441 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3% trehalose is the first listed.
NCT06655441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06655441 about?
NCT06655441 is a clinical study titled "The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function". The purpose of this research study is to evaluate the effects of trehalose, an ingredient found in commercially available artificial tears, on the corneal barrier function. The investigators will assess corneal dryness and measure the relative corneal epithelial "barrier" function (the degree to whi...
What is the current status of trial NCT06655441?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-03-01. Estimated completion is 2027-04.
What interventions are being tested in trial NCT06655441?
The interventions under investigation include: 3% trehalose (DRUG).
Who is sponsoring clinical trial NCT06655441?
This trial is sponsored by Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.